The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of Austin for 2022. Austin, Texas is home to a top-notch healthcare system and is regularly ranked among the best cities in the country in which to live and work. More businesses than ever are getting their start in the city, and it has become a hub of rapid tech industry growth for the state of Texas. Some experts are even predicting that Austin is on its way to becoming the new Silicon Valley. The growth in tech has encompassed all areas, including healthcare, and the city has seen remarkable advances come out of its wide variety of healthcare technology companies–thanks in no small part to the leaders directing their research and innovations.
Some of the influential honorees on this year’s list include Glenn Bilawsky, CEO of Discovery Life Sciences, which routinely manages hundreds of studies and expertly tests thousands of biospecimens simultaneously as a single vendor, eliminating time consuming and inefficient transfers of biospecimens or data between different vendors. Meanwhile, Co-Founder and CEO Anand Parikh’s Faeth Therapeutics is leveraging ground breaking research to starve cancer tumors of the nutrients they need to grow to improve the efficacy of conventional cancer therapies and extend patient survival. And COO Daniel Portillo’s Pro-Lab Diagnostics USA revolutionized the health and safety market with the TransVelope™specimen bag, and has since expanded its product offerings to include a superior line of latex agglutination products, a comprehensive organism storage and retrieval system, and a variety of general microbiology products.
The advances made by the healthcare technology companies represented on this year’s list are truly remarkable. From treatments for infectious diseases, to surgical implants, to kidney disease management and diagnostics, these companies are bringing desperately needed healthcare solutions to patients in Austin and around the world. Please join us in celebrating The Top 25 Healthcare Technology Leaders of Austin for 2022.
1. Mike Pintek
Company: Cardinal Health
Title: President of Nuclear & Precision Health Solutions
Mike Pintek is the President of Nuclear & Precision Health Solutions at Cardinal Health. Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With operations in more than 30 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. It is a crucial link between the clinical and operational sides of healthcare, delivering end-to-end solutions and data-driven insights that advance healthcare and improve lives every day. The company is navigating the complexities of healthcare and providing scaled solutions to help its customers thrive in a changing world. It strives to be a trusted healthcare partner by driving growth in evolving areas of healthcare, while building upon its distribution, products, and solutions to meet customer needs.
Pintek first joined Cardinal Health in 2014 as SVP of Commercial Operations and Business Development. Previously, he was COO at Luminex Corporation, and before that, an SVP and Global Head of Transfusion Medicine at Roche. Earlier in his career, he worked with GSK as a key account executive. Pintek earned an undergraduate degree in business administration from Central Michigan University.
2. John Potthoff
Company: Elligo Health Research
Title: Chief Executive Officer
John Potthoff is the Chief Executive Officer of Elligo Health Research, a healthcare-enabling research organization powered by the novel IntElligo® technology. The company accelerates clinical trials through healthcare with access to known patients and its HIPAA-compliant healthcare data, IntElligo® Research Stack technology, and its eSolutions Research Accelerator PatientSelect approach. As the largest Known Patient Access Network, the company’s ClinEdge Research Practice Management enables healthcare practices and research sites to participate in clinical trials as Research Ready. By adaptive engagement of known patients and physicians, these services dramatically accelerate the development of new pharmaceutical, biotechnology, and medical device and diagnostic products.
Before joining Elligo Health Research, Potthoff was CEO and President of Theorem Clinical Research, and before that, COO of INC Research. Earlier in his career, he worked with PPD as an executive director. Potthoff graduated from The University of Texas at Austin with a PhD in psychology, an MA in clinical psychology, and an undergraduate degree in psychology.
3. Glenn Bilawsky
Company: Discovery Life Sciences
Title: Chief Executive Officer
Glenn Bilawsky is the Chief Executive Officer of Discovery Life Sciences, a leading provider of highly characterized human biospecimens and cellular starting materials integrated with expert multi-omic analytical services to advance cell and gene therapy and precision medicine programs for cancer, infectious disease, and other complex conditions. Known as the Biospecimen and Biomarker Specialists™, the company’s robust biospecimen and biomarker platform is optimized for speed and large scale capacity. It routinely manages hundreds of studies and expertly tests thousands of biospecimens simultaneously as a single vendor – eliminating time consuming and inefficient transfers of biospecimens or data between different vendors. It also offers one of the largest recallable donor pools, Research Use Only (RUO) and clinical-grade (GMP) fresh and cryopreserved human cellular materials to support cell and gene therapy programs at any scale from start to finish.
Previously, Bilawsky was Group SVP for the Pharmaco LSR division of Applied Bioscience International (now PPD Inc.). From there, he went on to IQVIA (previously Quintiles Transnational, Inc.), before eventually rising to CEO at GPB Consulting, his most recent position prior to joining Discovery Life Sciences.
4. Drew Kramer
Company: Roivant Sciences
Title: Chief Information Officer
Drew Kramer is the Chief Information Officer of Roivant Sciences. Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. The company does this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across Roivant’s family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. The company focuses on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to its pharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines.
Kramer first joined Roivant in 2021. Previously, he was CIO at Pivotal, Inc., and before that, CISO at VMware. Earlier in his career, he worked with Compaq Computer Corporation as a director of technical operations. Kramer earned an undergraduate degree in computer science from Drew University.
5. Eduardo Perez
Title: Chief Financial Officer
Eduardo Perez is the Chief Financial Officer of ClearCorrect. ClearCorrect offers artificial teeth, dental metals, alloys, amalgams, and other equipment and instruments. Instead of the metal brackets and wires of traditional braces, ClearCorrect uses a series of clear, multi-layer, medical-grade removable plastic trays called aligners to straighten the teeth. These aligners fit directly onto the teeth and are virtually invisible when worn, and they're easy to remove for eating, drinking, and oral hygiene. The company works with more than 20,000 doctors, making it a leading manufacturer of clear aligner orthodontic products used to discreetly correct malocclusion in adults and teenagers. It offers a more affordable and doctor-friendly approach to clear aligner orthodontics, including a phase-based system that enhances flexibility and control for doctors. ClearCorrect serves patients worldwide.
Before joining ClearCorrect, Perez was CFO and Director of Finance and Administration at Straumann Group – Mexico, and before that, a finance manager and controller at Shire Pharmaceuticals Mexico. Earlier in his career, he worked with KPMG México as a senior tax auditor. Perez graduated from Universidad Panamericana with an MA and from IPN ESCA with an undergraduate degree in accountancy.
6. Anand Parikh
Company: Faeth Therapeutics
Title: Co-Founder and Chief Executive Officer
Anand Parikh is Co-Founder and Chief Executive Officer at Faeth Therapeutics, a cancer metabolism company. Faeth is leveraging ground breaking research from eminent cancer scientists to harness metabolism and precision nutrition to starve cancer tumors of the nutrients they need to grow, with the goal of improving the efficacy of conventional cancer therapies and extending patient survival.
Prior to Faeth, Parikh was the Head of Finance and General Counsel at Virta Health, which is helping to reverse type 2 diabetes in patients through a combination of carbohydrate restriction and remote patient monitoring. He previously was an attorney at Morrison & Foerster LLP. He received his undergraduate degree from the University of Michigan with a double major in political science and biology. Parikh received his law degree from New York University School of Law.
7. Daniel Portillo
Company: Pro-Lab Diagnostics USA
Title: Chief Operating Officer
Daniel Portillo is the Chief Operating Officer of Pro-Lab Diagnostics USA. In 1986, Pro-Lab Diagnostics effectively changed the U.S. Health and Safety market with the introduction of the original specimen transport bag - the TransVelope™. Since opening, Pro-Lab has successfully expanded its product offering to include a superior line of latex agglutination products, a comprehensive organism storage and retrieval system, and a variety of general microbiology products. Its mission is to provide high quality, cost-effective immunodiagnostic products and biological reagents to hospitals, private medical laboratories, veterinary laboratories, and other biological investigative laboratories. In keeping with its innovative tradition, Pro-Lab changed the way America performs Point-of-Care testing in OB-GYN and Birthing Clinics with the introduction of the AmnioTest™ Nitrazine Swab.
Most recently, the company has also expanded its product offering to include the OptiGene product line for molecular diagnostics. Pro-Lab Diagnostics is a forward-thinking group of purpose-driven people with the skills and desire to make a positive impact on healthcare and individuals lives. Portillo graduated from UT Health San Antonio with an undergraduate degree in clinical laboratory science.
8. Diane Wilfong
Company: Gilead Sciences
Title: Senior Vice President and Chief Accounting Officer
Diane Wilfong is the Senior Vice President and Chief Accounting Officer of Gilead Sciences. Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. It is a leader in developing HIV drugs such as Truvada and Genvoya. The company's drugs Sovaldi, Harvoni, and Epclusa have changed the landscape in the treatment of hepatitis C. With each new discovery and investigational drug candidate, Gilead seeks to improve the care of patients living with life-threatening diseases around the world. For more than 30 years, it has worked tirelessly to bring forward medicines for life-threatening diseases. It has built a culture of excellence that is fueled by a passion for improving the lives of people around the world.
Previously, Wilfong was a VP, Controller, and Principal Accounting Officer at CSC (Computer Sciences Corporation), and before that, an SVP, Controller, and Chief Accounting Officer at Caesars Entertainment Corporation. Earlier in her career, she worked with PricewaterhouseCoopers as an audit manager. Wilfong earned an undergraduate degree in accounting from the University of North Carolina at Chapel Hill.
9. Alexander Kenaston
Company: Syneos Health
Title: Vice President of Clinical Development
Alexander Kenaston is the Vice President of Clinical Development at Syneos Health, the only biopharmaceutical solutions organization purpose-built to accelerate customer success. Syneos leads with a product development mindset, strategically integrating clinical development, medical affairs, and commercial capabilities to address modern market realities. It brings together approximately 28,000 minds across more than 110 countries with a deep understanding of patient and physician behaviors and market dynamics. Together, they share insights, use the latest technologies, and apply advanced business practices to speed customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable, and inclusive culture that cares for colleagues, customers, patients, communities, and the environment.
Before joining Syneos Health, Kenaston was an Executive Director of CNS Clinical Development at INC Research, and before that, a fellow of the national institute for diabetes, digestive, and kidney diseases at the University of Texas at Austin. Earlier in his career, he worked with Seton Family of Hospitals as a registered nurse II. Kenaston graduated from The University of Texas at Austin with a PhD in pharmacology and toxicology, from the University of Florida with an MS in toxicology, and from The University of Texas at Austin with an undergraduate degree in nursing.
10. Stacy Weil
Company: Premier Research
Title: Senior Vice President of Clinical Informatics
Stacy Weil is the Senior Vice President of Clinical Informatics for Premier Research, a provider of research and development consulting services intended for the biotechnology and pharmaceutical industries. It is a 1,500-employee strong company that operates in more than 20 countries, delivering unmatched expertise, operational skills, and dedication to meeting customers’ most challenging needs. It is home to some of the brightest minds in clinical development today—people who apply their best thinking to every project, recognizing that what they do significantly affects the lives and well-being of customers, patients, physicians, and colleagues. The company offers product development and regulatory consulting, clinical research development, and medical device development support in a broad range of fields such as rare diseases, cell therapy, oncology, dermatology, and neuroscience, thereby providing a strategic combination of industry acumen, global compliance, and therapeutic expertise to its clients.
Previously, Weil was therapeutic head of project management at PPD. From there, she went on to Patient Identification Platform (Patient I.P.) as VP of clinical data operations, her most recent position prior to joining Premier Research. Weil graduated from The University of Texas Health Science Center at Houston with a doctor of health informatics and an MS in biomedical informatics, from the University of the Incarnate Word with an MS in nutrition, and from Marquette University with an undergraduate degree.
11. Kevin Carroll
Title: Vice President of Prosthetics
Kevin Carroll is the Vice President of Prosthetics at Hanger. Hanger, Inc. is a leading national provider of comprehensive, outcomes-based orthotic and prosthetic (O&P) services that assist in enhancing or restoring the physical capabilities of patients with disabilities or injuries, through its Patient Care segment, with approximately 875 Hanger Clinic locations nationwide. Through its Products & Services segment, Hanger distributes branded and private label O&P devices, products and components, and provides rehabilitative solutions. Hanger is a purpose-driven company with a vision to lead the O&P markets by providing superior patient care, outcomes, services and value, aimed at empowering human potential. It works to find new ways to return personal independence to those with physical challenges, while remaining true to the superior clinical outcomes and customer service in which the company is grounded.
Carroll first joined Hangerin 1984. Previously, he served on the board of directors for the American Academy of Orthotists & Prosthetists and is currently an advisory board member for The O&P EDGE. Carroll earned an MS in gerontology.
12. Francesca Estey
Title: Vice President of Marketing
Francesca Estey is the Vice President of Marketing of Enovis, a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, extraordinary talent, and innovation, it “creates better together” by partnering with healthcare professionals. Its extensive range of products, services, and integrated technologies fuel active lifestyles.
Before joining Enovis, Estey was a senior group marketing manager at Stryker. She graduated from Georgetown University with an undergraduate degree in health studies.
13. Jeff Zigler
Title: Vice President of Market Access and Reimbursement
Jeff Zigler is the Vice President of Market Access and Reimbursement at SI-BONE, a medical device company that develops and commercializes a proprietary, minimally invasive surgical implant system in the United States and internationally. It offers the iFuse Implant System®, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE is focused on helping patients in one of the most underserved, underdiagnosed, and undertreated areas in orthopedics, the sacroiliac (SI) joint. SI-BONE developed an innovative, patented implant to fuse the SI joint. The iFuse provides a less invasive alternative to traditional SI joint fusion surgery and uses the same titanium implant technology that has been used in the ENDO-FUSE System. To date, more than 65,000 minimally invasive surgical SI joint fusions have been performed with the iFuse Implant System by more than 2,400 surgeons worldwide.
Previously, Zigler served as director of business development for Lawline.com. From there, he went on to MCRA, before eventually rising to senior director of market access, health economics, and reimbursement at Zimmer Biomet, his most recent position prior to joining SI-BONE. Zigler graduated from New York Law School with a JD, and from The University of Texas at Austin with an undergraduate degree in corporate communication.
14. Julie Glasser
Company: Sangamo Therapeutics
Title: Vice President and Head of Corporate Law
Julie Glasser is the Vice President and Head of Corporate Law at Sangamo Therapeutics. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today’s medicine can only offer symptom management at best. Its rare disease clinical programs are feeding insights across its portfolio and paving the way for research and preclinical programs across larger patient populations. For Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. Its scientists are leaders in the discovery, research, and development of technologies enabling gene-based therapeutic development. Sangamo is currently conducting clinical trials, including the first ever in vivo human genome editing studies.
Previously, Glasser was a deputy general counsel, deputy compliance officer, and assistant corporate secretary at Luminex Corporation, and before that, a corporate counsel at Thermo Fisher Scientific. Earlier in her career, she worked with Cravath, Swaine & Moore LLP as a corporate associate. Glasser earned a JD from Columbia Law School, an MA in Russian, East European, and Eurasian studies, and an undergraduate degree in comparative literature from Stanford University.
15. Allison Trucillo
Title: Vice President of Medical Affairs
Allison Trucillo is the Vice President of Medical Affairs of Renalytix, an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs. It is the founder and global leader in the new field of Bioprognosis™ for kidney health. It has engineered a proprietary solution that successfully enables early-stage, progression risk assessment when it counts the most. Renalytix’s proprietary platform, KidneyIntelXTM, is at the core of its solution offering. With KidneyIntelX, Renalytix takes diverse and proprietary data inputs and maximizes their value through its AI-enabled algorithm. This allows the company to generate an accurate kidney disease risk score – identifying patients with kidneys at the most risk – to guide ongoing, clinical decisions.
Before joining Renalytix, Trucillo was a senior director of medical affairs at Aeglea BioTherapeutics, and before that, a regional director of the medical science liaison team at Insmed Incorporated. Earlier in her career, she worked with Abbott Laboratories as a medical science liaison. Trucillo graduated from Baylor College of Medicine with an MD, from Rutgers Business School with an MBA, and from The University of Texas at Austin with an undergraduate degree in zoology.
16. Thomas Reslewic
Company: LI-COR Biosciences
Title: Chief Executive Officer
Thomas Reslewic is the Chief Executive Officer of LI-COR Biosciences, a leading biotechnology innovator of imaging systems, analysis software, infrared reagents, and consumables for targeted therapeutics research, protein studies, and microbial-related drug development. Its mission is to provide complete research solutions for quantitative Western blots with the Odyssey® Infrared Imaging Systems, Empiria Studio® Software and Template Designer, and IRDye® infrared reagent dyes. From studying targeted therapeutics with the Pearl Trilogy® Small Animal Imaging System to analyzing the human microbiome for drug development, LI-COR’s global team of experienced scientists is ready to support diverse research initiatives. LI-COR also offers data integrity tools, laboratory best practices, and professional training courses in an effort to help scientists improve the human condition and solve the challenges that are facing humanity.
Prior to LI-COR, Reslewic served as President, CEO, and Director at LeCroy Corporation (now Teledyne LeCroy). From there, he went on to Teledyne Technologies Incorporated, before eventually rising to executive in residence at Battery Ventures, his most recent position prior to joining LI-COR Biosciences. Reslewic graduated from the University of Oregon with an MBA and from College of the Holy Cross with an undergraduate degree in physics.
17. Jason Kim
Company: Molecular Templates
Title: President and Chief Operating Officer
Jason Kim is the President and Chief Operating Officer of Molecular Templates. Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform with unique mechanisms of actions which are highly differentiated from ADCs. The company is developing MT-6402, designed to induce potent anti-tumor effects; MT-5111, shown pre-clinically to bind and kill HER2 (a protein that helps breast cancer cells grow quickly) expressing cells; and MT-0169, designed to treat relapsed/refractory myeloma.
Previously, Kim was a corporate developer at OSI Pharmaceuticals, and before that, he co-founded Summa Life Sciences, LLC. Earlier in his career, he worked with ImClone Systems as a director of business development. Kim earned an MBA from The Wharton School of the University of Pennsylvania and an undergraduate degree in neuroscience from Wesleyan University.
18. Jennifer Hoskovec
Company: BillionToOne, Inc.
Title: Senior Director of Medical Affairs
Jennifer Hoskovec is the Senior Director of Medical Affairs at BillionToOne. BillionToOne is a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. It works to improve disease detection by counting molecules with their proprietary molecular counting platform.
As a certified genetic counselor with more than 17 years of clinical experience, Hoskovec is committed to ensuring patients and providers are supported and educated about the options and utility of prenatal genetic screening. She joined BillionToOne after 17 years as a prenatal genetic counselor at UTHealth, where she led a team of genetic counselors providing patient care in Maternal Fetal Medicine clinics across the city of Houston. Hoskovec has extensive volunteer and leadership experience within national medical societies such as the American College of Obstetricians and Gynecologists and the National Society of Genetic Counselors (NSGC). She served as president of the NSGC in 2014.
Hoskovec earned her Master of Science in genetic counseling from the University of Texas Health Science Center in Houston and her Bachelor of Science in biology with a minor in chemistry from Truman State University.
19. Kara Connell
Title: Director of Enrollment and Customer Success
Kara Connell is the Director of Enrollment and Customer Success at NeuFit. NeuFit is a medical device company that is shifting the paradigm of rehabilitation and recovery by focusing on the nervous system. Using specialized direct current technology, the company’s NEUBIE device helps patients restore function lost due to neurological injuries or conditions; recover faster from pain, injury, and surgery; and optimize performance. Connell has helped lead the company’s growth from only a few employees to one of the fastest-growing companies in the U.S., recently named the 51st fastest growing private healthcare company by INC 5000.
Connell began her career in advertising sales with new business and enterprise-level accounts. Prior to joining the NeuFit team, she served in the operating room as a representative for Integra LifeSciences in orthopedics and biologics. She holds an undergraduate degree in biology from the University of Texas at Austin.
20. Thomas Wrona
Title: Senior Vice President of Intellectual Property
Thomas Wrona is the Senior Vice President of Intellectual Property at Absci Corp, the artificial intelligence-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Absci built its Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with Absci to create the next generation of protein-based drugs, including those that may be impossible to make with other technologies. Its goal is to enable the development of better medicines by Translating Ideas into Drugs™.
Before joining Absci, Wrona was a senior counsel at Amgen, and before that, a special counsel at Marshall, Gerstein & Borun LLP. Earlier in his career, he worked with Arnold, White & Durkee as a scientific advisor. Wrona graduated from the University of Illinois Chicago School of Law with a JD in intellectual property, from The University of Texas at Austin with a PhD in microbiology, and from the University of Illinois Urbana-Champaign with an undergraduate degree in microbiology.
21. Brent Hauser
Title: Senior Vice President of Global Sales
Brent Hauser is the Senior Vice President of Global Sales at InBrace. InBrace is changing the face of orthodontics and revolutionizing orthodontic technology one mouth at a time. It is transforming not only how teeth are adjusted, but the entire patient experience. How it works. How it feels. How it looks. Starting from day one. Because everyone deserves to feel confident sharing their truest selves with the world. Created by orthodontists, InBrace intelligently and intuitively moves teeth in a way that’s gentler, faster, and more discreet. Its decades of passion in this industry and its desire for complete patient satisfaction from the inside out are what guided it to challenge the status quo and create InBrace.
Hauser first got his start in 2002 as a director of sales of APAC at Solta Medical, Inc. From there, he went on to ZELTIQ, before eventually rising to VP of Marketing at AbbVie, his most recent position prior to joining InBrace. Hauser graduated from Stanford University.
22. David West
Title: Vice President of Sales, Eastern and Central USA
David West is the Vice President of Sales for Eastern and Central USA at BIOLASE. BIOLASE, Inc. is the world’s leading innovator in dental lasers. It is a medical device company and global market leader in the manufacturing and marketing of proprietary dental laser systems that enable dentists and dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and surgical applications. BIOLASE's laser systems are designed to provide clinically superior, patient-friendly results for many types of common dental procedures compared to those achieved with traditional instruments. Its purpose is to restore and repair dental anatomy, alleviate pain, and reduce fear and anxiety related to dentistry in order to improve patient quality of life. It enables its customers to elevate their standard of dental care and improve patient outcomes through laser technology.
West first joined BIOLASE in 2012. He has over 30 years of business-to-business sales experience and leadership, and his sales knowledge is specialized in a fast-paced, solution-based selling methodology with disruptive technology and clinical environments. West earned an undergraduate degree in health and human development from Penn State University.
23. Cinta Burgos
Company: Azzur Group
Title: Vice President of Consulting Services
Cinta Burgos is the Vice President of Consulting Services at Azzur Group, a premier professional service provider for the health and life sciences industry. From Discovery to Delivery™, Azzur Group provides the life science community with full lifecycle solutions for all GxP needs. Transitioning from early-phase manufacturing to full-scale operations, the company helps make critical decisions early on, allowing clients to execute risk-averse strategies and processes to get product into patients' hands faster—from Azzur Cleanrooms on Demand™ facilities, to labs, training centers, and consulting and advisory offices across the nation. With four decades of service to the industry, the company has become a trusted partner to leading pharmaceutical, biotechnology, medical device, and healthcare companies.
Before joining Azzur Group, Burgos was CEO and QA consultant for The Biotech Box, and before that, an independent consultant at CB Biotech Consulting. Earlier in her career, she worked with Aphios Corporation as an R&D engineer. Burgos graduated from the University of California, San Diego with an undergraduate degree in biophysics.
24. Boris Fischer
Company: Apollo Endosurgery
Title: Vice President of Business Process and Systems
Boris Fischer is the Vice President of Business Process and Systems at Apollo Endosurgery, a medical technology company focused on the development of next-generation, less invasive devices to advance therapeutic endoscopy designed to treat a variety of gastrointestinal conditions, including closure of gastrointestinal defects, managing gastrointestinal complications, and the treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs.
Fischer first got his start in 1996 as a project manager at Opel. From there, he went on to General Motors, before eventually rising to VP of Technology, Systems & Infrastructure at Smith & Nephew Orthopaedics, his most recent position prior to joining Apollo Endosurgery. Fischer graduated from Coventry University with a PhD and MS in computer aided engineering, and from the Northwestern University Kellogg School of Management with an MBA.
25. Ally Masten
Company: Vikor Scientific
Title: President of Sales for Long Term Care
Ally Masten is the President of Sales for Long Term Care at Vikor Scientific. Vikor Scientific™ is a molecular diagnostics company focused on antibiotic stewardship and tangible solutions for the practice of value-based medicine in the treatment of infectious disease. It provides clinicians with the most advanced molecular methodology for pathogen detection, quantification, and resistance gene identification. These results are delivered through a value-based technology platform, ABXAssist™, which incorporates sensitivity and susceptibility patterns from Sanford Guide, medication costs, antibiotic spectrum of activity, and FDA guidance. The end product is a patient-centered, value-based care solution that enables providers to make informed treatment decisions that could avoid inappropriate therapy, excess costs, adverse drug events, and the progression of disease. From the beginning, the motivation to create diverse, yet sophisticated molecular pathogen and resistance panels for providers was driven by the need to establish a solution to thwart the growing problem of antibiotic resistance.
Masten first joined Vikor Scientific in 2020 as an account manager before working her way up to VP of Long Term Care. Previously, she was a sales manager at Cintas. Masten earned an undergraduate degree in liberal arts and sciences from Oregon State University.